Technical Data
CA19-9 Cancer Antigen (Pancreatic, GI or Ovarian Tumor Antigen, Sialyl Lewis a)
Carbohydrate antigen 19-9 (CA 19-9) is a protein that exists on the surface of certain cells and is the most frequently used tumor markers in the clinical setting of cancer. It does not cause cancer; rather, it is a protein that is shed by the tumor cells, making it useful as a tumor marker to follow the course of the cancer. CA 19-9 is elevated in most patients with advanced pancreatic cancer, colorectal cancer, lung cancer, gall bladder cancer, gall stones, pancreatitis, cystic fibrosis, and liver disease. Very small amounts of CA 19-9 may also be found in healthy patients. Besides in patients with Lewis antigen blood group type, CA 19-9 is not elevated even in pancreatic cancers as they have a deficiency of fucosyltransferase needed to synthesize CA 19-9.

Suitable for use in Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Immunohistochemistry (formalin fixed paraffin embedded): 1:25-1:50
Immunohistochemistry: Frozen
Optimal dilutions to be determined by the researcher.

Positive Control:
Colon carcinoma

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
500ul-20CBlue IceHumanMouse
Not determined.
Human colorectal adenocarcinoma cell line COLO 205. Cellular Localization: Cytoplasmic.
Supplied as a liquid, 0.05% sodium azide.
Recognizes human CA 19-9.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Haglund et al. Br J Cancer 60: 845, 1989. 2. Johansson et al. Tumor Biol 12: 159, 1991. 3. Kuusela et al. Br J Cancer 63: 636, 1991.